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Abstract
Background: Currently, it remains unclear, if patients with colon cancer and synchronous unresectable metastases
who present without severe symptoms should undergo resection of the primary tumour prior to systemic
chemotherapy. Resection of the primary tumour may be associated with significant morbidity and delays the
beginning of chemotherapy. However, it may prevent local symptoms and may, moreover, prolong survival as has
been demonstrated in patients with metastatic renal cell carcinoma. It is the aim of the present randomised
controlled trial to evaluate the efficacy of primary tumour resection prior to systemic chemotherapy to prolong
survival in patients with newly diagnosed colon cancer who are not amenable to curative therapy.
Methods/design: The SYNCHRONOUS trial is a multicentre, randomised, controlled, superiority trial with a two-
group parallel design. Colon cancer patients with synchronous unresectable metastases are eligible for inclusion.
Exclusion criteria are primary tumour-related symptoms, inability to tolerate surgery and/or systemic chemotherapy
and history of another primary cancer. Resection of the primary tumour as well as systemic chemotherapy is
provided according to the standards of the participating institution. The primary endpoint is overall survival that is
assessed with a minimum follow-up of 36 months. Furthermore, it is the objective of the trial to assess the safety
of both treatment strategies as well as quality of life.
Discussion: The SYNCHRONOUS trial is a multicentre, randomised, controlled trial to assess the efficacy and safety
of primary tumour resection before beginning of systemic chemotherapy in patients with metastatic colon cancer
not amenable to curative therapy.
Trial registration: ISRCTN30964555
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In Germany colorectal cancer represents the second
most common malignancy among both sexes with a
total annual incidence of 70.000 cases (50.000 patients
with colon cancer) as recently reported by the Society of
Epidemiological Cancer Registers in Germany (GEKID)
and the Robert-Koch Institute http://www.gekid.de. At
diagnosis, about 25% of colon cancer patients (i.e.
12.500 patients each year) present with distant metas-
tases (i.e. UICC stage IV) [1]. The vast majority of these
patients (i.e. 10.000 patients) remain candidates for
exclusive palliative treatment [2,3]. It has been shown
that some 4% of these patients present symptoms
requiring urgent admission [4]. At present, the two prin-
cipal treatment strategies for patients without severe
tumour-related symptoms are: colonic resection fol-
lowed by chemotherapy or immediate chemotherapy
without prior surgery [5]. In theory, surgery delays the
start of effective systemic therapy and bears the risk of
severe complications and mortality. Surgery may, how-
ever, prevent development of complications caused by
the primary tumour that may subsequently require
emergency interventions that are associated with
increased peri-operative mortality as well as less favour-
able long-term outcome. Given the fact that patients
with metastatic disease have prolonged survival (2 years
or more) with modern systemic therapy, the need for
(delayed) emergency surgery may be increasing. Further-
more, removal of the primary tumour may positively
affect overall survival. Although the underlying mechan-
isms remain unexplained at this stage, a benefit for
resection of the primary tumour in stage IV disease has
already been demonstrated in two randomised con-
trolled trials (RCT) in patients suffering from metastatic
renal cancer [6,7] as well as nonrandomised studies in
patients with metastatic breast cancer [8,9]. The present
trial is designed to evaluate whether patients benefit
from surgery of the primary tumour in the setting of
synchronous metastatic colon cancer not amenable to
curative therapy.
Existing evidence and need for the trial
Assuming a hazard ratio (HR) of 0.67 and 0.5, respec-
tively, two well-designed RCTs could already demon-
strate a statistically significant survival benefit for
patients with metastatic renal cancer undergoing
nephrectomy prior to systemic therapy. Flanigan et al.
reported median overall survival times of 11.1 vs. 8.1
months (p = 0.01) [6] and Mickisch et al. of 17 vs. 7
months (p = 0.03) [7] in favour of nephrectomy.
Two recent systematic reviews detected very low quan-
titative as well as qualitative evidence for optimal man-
agement of asymptomatic patients diagnosed with colon
cancer and synchronous metastases not amenable to
curative therapy [5,10]. So far, only retrospective or pro-
spective case series have been conducted that almost
exclusively report mono-institutional experiences with
small sample sizes. These studies do not allow clear con-
clusions, as: a) they were not hypothesis driven trials and
thus lack power calculations; b) they were confounded by
selection bias, as patients with favourable performance/
prognostic parameters are more likely to undergo sur-
gery; c) they included patients with cancers of both colon
and rectum; d) they were mostly conducted prior to
introduction of modern chemotherapeutic regimens that
enable median overall survival times of 17-23 months for
patients with metastatic colorectal cancer as indicated by
several Phase III trials [11-13]. Against the background of
these potential confounders the systematic review by
Scheer et al. [10] revealed a similar benefit in median sur-
vival for patients undergoing resection of the primary
tumour prior to systemic therapy in the two largest stu-
dies (Ruo et al.: 16 vs. 9 months [14]; Tebbutt et al.: 14
vs. 8.2 months [15]), whereas there was no difference in
overall survival in the remaining studies. Noteworthy, the
study by Tebbutt provided detailed information on com-
plication rates showing no differences in incidence of
intestinal obstruction (p = 0.96), peritonitis (p = 0.13)
and gastrointestinal haemorrhage requiring hospital
admission (p = 1.0) between both study groups [15].
Aim of this trial
There is still considerable uncertainty, if colon cancer
patients who present with incurable disease and little or
no symptoms should undergo resection of the primary
tumour prior to systemic therapy. A high proportion of
patients undergo initial colonic resection [16]. However,
this invasive procedure has a known morbidity of about
20-30% and mortality of up to 8% [17,18]. Thus, indica-
tion for colonic resection in patients without marked
symptoms needs to be justified by a relevant benefit in
overall survival. It is the aim of the SYNCHRONOUS
trial to evaluate efficacy and safety of primary tumour
resection prior to chemotherapy in patients with colon
cancer and synchronous, unresectable metastases. Given
the proven survival benefit for surgery in patients with
metastatic renal cancer and considering the more con-
servative assumption applied in the RCT by Flanigan et
al. [6], colonic resection may estimably prolong overall
survival from 20 months in patients without surgery to
26 months. An effect of this size would represent a
clinically relevant improvement and is in accordance
with the retrospective studies by Tebbutt et al. and Ruo
et al. [14,15]. If colonic resection has no benefit on sur-
vival, the current clinical practice can be stopped and
procedure related morbidity and mortality prevented.
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Trial design and randomisation
The SYNCHRNOUS trial is a randomised, controlled,
multicentre, confirmatory study comparing resection of
the primary tumour versus no resection prior to sys-
temic therapy in patients with colon cancer and syn-
chronous metastases not amenable to curative therapy.
After screening for eligibility and informed consent is
obtained, patients are randomised in a 1:1 ratio into one
of the following study arms:
￿ Resection of the primary tumour followed by sys-
temic therapy (experimental arm)
￿ Systemic therapy alone (control arm)
Patients are randomised stratified for centre using a
web-based, central randomisation and registration sys-
tem http://www.randomizer.at.
Treatment according to randomisation, i.e. resection
of the primary tumour or first cycle of systemic therapy
must be carried out within 14 days after randomisation.
Trial organisation
The SYNCHRONOUS trial will be conducted as an
intergroup trial of the Study Centre of the German Sur-
gical Society (SDGC), the German Surgical Network of
Clinical Studies (CHIR-Net) together with the Colorectal
Study Group of the Arbeitsgemeinschaft Internistische
Onkologie (AIO) of the German Cancer Society and the
Association of Certified Intestinal Centres (Arbeitsge-
meinschaft Zertifizierter Darmzentren). The SDGC is
responsible for the project management of the trial.
Patient recruitment will take place at more than 60 trial
centres throughout Europe that will be chosen out of a
total of more than 100 institutions with interest in parti-
cipation in the study.
Trial population and patient recruitment
At each participating centre all consecutive patients with
the new diagnosis of colon cancer and synchronous,
unresectable metastases will be screened for eligibility to
be enrolled in the SYNCHRONOUS trial. An interdisci-
plinary team at each trial centre including a surgeon
and a medical oncologist/gastroenterologist determines,
if patients are not amenable to curative therapy and
may thus be considered for inclusion in the SYNCHRO-
NOUS trial.
Inclusion criteria
￿ Newly diagnosed, histologically confirmed colon
cancer
￿ Synchronous metastases not amenable to curative
therapy:
Assessment by an interdisciplinary team at each trial
centre including a surgeon and a medical oncologist or
gastroenterologist.
￿ Resectable primary tumour
￿ ECOG performance status of 0, 1, or 2
￿ Patient considered to tolerate surgery and che-
motherapy by the local interdisciplinary team
￿ ≥ 18 years of age
￿ Written informed consent
Exclusion criteria
￿ Rectal cancer (tumour up to 12 cm from the anal
verge)
￿ Tumour-related symptoms or diagnostic findings
requiring urgent surgery
Definition of tumour-related symptoms: e.g. lower gas-
trointestinal bleeding requiring transfusion, bowel
obstruction, tumour perforation or intractable pain at
site of primary tumour.
Definition of diagnostic findings: e.g. obstructing
tumour that cannot be passed by colonoscope.
￿ Patients not eligible for surgery (ASA ≥ IV)
￿ Unequivocal extensive peritoneal metastases
￿ Chemo- or radiotherapy during the past 6 months
￿ History of another primary cancer
Exceptions: curatively treated in situ cervical cancer,
curatively resected non-melanoma skin cancer or other
primary solid tumour curatively treated with no known
active disease present and no treatment administered for
≥ 5 years prior to randomisation.
￿ Expected lack of compliance
Trial interventions
Experimental arm: resection of the primary tumour prior to
systemic therapy
Patients in the experimental arm will undergo resection
of the primary tumour prior to receiving systemic che-
motherapy. Surgery has to be performed within 14 days
after randomisation. Systemic therapy should be started
within 8 weeks after surgery.
The type of surgical procedure depends on the location
of the tumour and is thus performed as (extended) right
hemicolectomy, (extended) left hemicolectomy, rectosig-
moid resection or subtotal colectomy. In certain cases sur-
geons may perform a segmental colonic resection, if
considered adequate by the executing surgeon. If possible
and considered safe for the patient, resections should be
performed with adequate local lymphadenectomy as it is
associated with low additional morbidity [19]. However,
the decision to perform a lymphadenectomy is left at the
discretion of the executing surgeon and is documented in
the CRF. A complete (R0) resection of the tumour should
be performed. However, if a R0 resection is not considered
to be safe and adequate (e.g. due to involvement of adja-
cent structures such as the ureter, stomach, pancreas etc.)
surgeons may perform a R2 resection. The kind of resec-
tion should be documented in the case report forms (CRF).
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perform a primary anastomosis or to create a stoma
after colonic resection. Open and laparoscopic colect-
omy may be performed.
The principles of systemic therapy in the experimental
arm are identical to those for the control arm.
Control arm: systemic therapy without previous resection of
the primary tumour
Patients in the control arm receive primary systemic che-
motherapy without previous resection of the primary
tumour. Systemic therapy has to start within 14 days after
randomisation. There is no predefined protocol of sys-
temic therapy. The executing medical oncologist deter-
mines patients’ treatment. Chemotherapy according to
local practice and/or current guidelines is recommended
(e.g. the German S3-guideline for colorectal cancer [20]).
Examples for such chemotherapy regimens are (oral)
fluoropyrimidin-based combination therapy with Oxalipla-
tin or Irinotecan such as FOLFOX-4, FOLFOX-6, FOL-
FIRI, CAPOX, XELOX with or without targeted therapy
such as Bevacizumab or Cetuximab for K-ras wild-type
tumours). However, as actually administered therapy
depends on various factors (e.g. patients’ comorbidities,
development of toxicities) and may change over time due
to emerging evidence, the administered systemic therapy
is documented carefully for each patient in both study
arms and is considered as a covariate in multivariate ana-
lysis (in addition to centre as factor in multivariate analy-
sis). At each follow-up visit documentation of systemic
therapy includes the administered agents (protocol), possi-
ble dose reductions and delays of planned chemotherapy
cycles. Dose adjustment, duration and termination of sys-
temic therapy are at the discretion of the executing medi-
cal oncologist. In case of progression systemic therapy
may be switched to a second (and third) line regimen. The
choice of the second and third line regimen is also at the
discretion of the executing medical oncologist.
Patients may also discontinue systemic therapy in the
following instances:
￿ Occurrence of adverse events, if discontinuation is
desired or considered necessary by the patient and/or
the medical oncologist
￿ Request by the patient
￿ Occurrence of pregnancy during treatment
￿ Lack of subject compliance
In case of adverse events requiring discontinuation,
systemic therapy may be restarted, if considered appro-
priate by the executing medical oncologist.
Patients may be enrolled in further chemotherapy
trials.
Additional treatments
Owing to the palliative situation, patients in both
treatment arms may receive any concomitant
medications or treatments deemed necessary to pro-
vide adequate supportive care. In particular, patients
may receive analgetic and antiemetic therapy for relief
of symptoms directly related to the disease and/or
chemotherapy.
Based on data of randomised phase III trials 6-10% of
patients with colorectal cancer and unresectable metas-
tases may become operable after treatment with modern
chemotherapy regimens and subsequently undergo sur-
gery with curative attempt [13,21]. Patients who become
operable during chemotherapy may undergo treatment
of the primary tumour (patients in the control arm) or
metastases (patients in the experimental and control
arm) with curative intent. In this scenario, patients may
also undergo radiofrequency ablation (RFA) of meta-
static lesions with curative attempt. The decision to
initiate curative therapy has to be made by the members
of the interdisciplinary team at the recruiting institution.
These patients will be included in the intention-to-treat
analysis.
Patients randomised to the control arm may, more-
over, undergo interventional therapy for local complica-
tions (e.g. colonic stents, laser therapy). However,
development of local complications will be documented
as a secondary endpoint as will be the need for interven-
tions. The decision to refer patients in the control arm
for palliative tumour resection due to local complica-
tions is at the discretion of the multidisciplinary team at
the recruiting institution.
The duration of treatment breaks before and after
interventional procedures is at the discretion of the mul-
tidisciplinary team at the recruiting site according to the
actual extent of the procedure.
Study objectives and endpoints
The primary objective of the present trial is to investi-
gate, whether resection of the primary tumour prolongs
survival of patients with colon cancer and synchronous
metastases not amenable to curative therapy. The pri-
mary hypothesis is that resection of the primary tumour
prolongs survival from 20 to 26 months compared to
systemic therapy without prior tumour resection.
It is the secondary objective of the trial to evaluate
short- and long-term safety of both treatment strategies
as well as subsequent curative procedures, the course of
tumour markers and patients’ quality of life.
Primary endpoint
The primary efficacy endpoint is overall survival,
defined as time from randomisation date to date of
death due to any reason. After randomisation patients
will be followed up at intervals of three months for a
minimum duration of 36 months or until death. Patients
who have not died by the end of follow-up will be cen-
sored at their last contact date, as will be those patients
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other than death (e.g. loss to follow-up).
Secondary endpoints
￿ Time-to-development of primary tumour related local
symptoms (control arm):
Time from randomisation date to date of first
appearance of tumour related local symptoms
requiring hospitalisation and/or therapy (except for
use of laxatives)
￿ Primary tumour complications (control arm):
Frequency and kind of local complications related to
the primary tumour:
- Lower gastrointestinal bleeding: Evidence of lower
gastrointestinal bleeding such as positive Haemoccult
test or apparent blood that is not attributable to other
causes (e.g. haemorrhoids), results in a drop of systemic
haemoglobin and requires transfusion or interventional
therapy (e.g. endoscopic control of haemorrhage)
- Bowel obstruction: Symptoms of ileus/subileus, i.e.
abdominal pain and absence of bowel movement
together with evidence of bowel obstruction from
abdominal x-ray or CT scan that require hospitalisa-
tion and/or interventional therapy (e.g. stent place-
ment, laser recanalisation, operation with bowel
resection, creation of a stoma or bypass)
- Tumour perforation: Clinical symptoms suspicious
of intestinal perforation (e.g. abdominal pain and
tenderness, fever, elevated infectious parameters)
together with evidence of bowel perforation by ima-
ging (free air on abdominal x-ray, CT scan) or on
laparotomy.
￿ Intervention due to primary tumour complication
(control arm):
￿ Frequency and kind of operative or non-operative
interventional therapy for complications of the primary
tumour:
- Operation with colonic resection
- Operation with creation of a stoma
- Operation with creation of an intestinal bypass
- Endoscopic placement of a stent
- Endoscopic recanalisation (e.g. by laser)
- Endoscopic control of haemorrhage (e.g. clips, sub-
mucosal injections)
￿ Administration of systemic therapy (experimental
and control arm):
Proportion of patients, who actually receive systemic
therapy. Furthermore, the administered agents (i.e.
chemotherapy protocol), dose reductions and delays
of chemotherapy cycles are documented for both
study arms.
￿ Peri-operative morbidity (experimental arm):
Frequency and kind of peri-operative complications
after resection of the primary tumour until post-
operative day 30 (Visit 2a). Complications are graded
according to the Dindo classification (see Additional
file 1: Appendix A).
- Anastomotic leakage
The diagnosis of anastomotic leakage after colonic
resection is made considering the proposed defini-
tion of anastomotic leakage after rectal resection
[22]: Defect of the intestinal wall integrity at the
anastomotic site leading to a communication
between the intra- and extraluminal compartments
(detection by imaging or on re-laparotomy). An
abscess close to the anastomosis is also considered
as anastomotic leakage. The severity of an anastomo-
tic leakage is graded as follows:
Grade A: Anastomotic leakage requiring no active
therapeutic intervention.
Grade B: Anastomotic leakage requiring active thera-
peutic intervention but manageable without re-
laparotomy.
Grade C: Anastomotic leakage requiring re-
laparotomy.
- Postoperative ileus
Obstructive symptoms after surgery (e.g. abdominal
distension, vomiting) with the need to stop food
intake and/or insert a gastric tube. Radiological con-
firmation by plain abdominal x-ray or CT scan is
required.
- Surgical site infection (CDC-Definition, see Addi-
tional file 1: Appendix B)
- Intraabdominal Abscess
Intraabdominal collection of purulent or infected
f l u i d( c o n f i r m e db yc u l t u r e )c o n f i r m e db yi n t e r v e n -
tional drainage or on surgical re-intervention.
- Postoperative haemorrhage
Drop of systemic haemoglobin ≥ 3 g/dl compared to
postoperative baseline level and/or need for transfu-
sion of > 2 units of packed red blood cells due to
intra-abdominal haemorrhage as indicated by blood
loss via the abdominal drains and/or free abdominal
fluid/hematoma on imaging/re-operation.
- Deep vein thrombosis
Clinical evidence (e.g. painful, swollen, warm, livid
leg) of a deep thrombosis located in a leg or pelvic
vein confirmed by duplex sonography or CT-angio-
graphy, which was not previously known.
- Pulmonary embolism
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monary embolism confirmed by spiral computed
tomography or lung perfusion scintigraphy.
- Pulmonary infection
At least 3 of 4 of the following: temperature > 37.5°
C, purulent tracheal secretion, white blood count >
12 000 or < 4,500/ml, elevated CRP level together
with radiological evidence of pulmonary infection.
- Renal failure
Postoperative doubling of pre-operative serum crea-
tinine level or need for dialysis or hemofiltration (in
patients who were not on dialysis pre-operatively).
- Cerebral insult
Clinical symptoms suspicious of an (ischemic or
non-ischemic) cerebrovascular event with confirma-
tion by CT or MRT.
- Myocardial infarction
Electrocardiogram (NSTEMI or STEMI) and enzyme
(Troponin I) changes suggestive of myocardial
infarction or evidence of myocardial infarction on
coronary angiogram.
- Hospital stay
The length of hospital stay registered from the first
day after the operation until the day of discharge.
￿ Peri-operative mortality (experimental arm):
30-day mortality or in-hospital mortality during
initial hospital stay for resection of the primary
tumour (i.e. deaths occurring after patients’ dis-
charge from the hospital but within 30 days after
resection of the primary tumour are documented as
peri-operative mortality).
￿ Interventions with curative intent (experimental and
control arm):
Frequency and kind of interventions performed with
curative intent:
- Potentially curative resection of the primary
tumour and metastases (control arm)
- Potentially curative resection of metastases (experi-
mental arm).
- Radiofrequency ablation (RFA) of metastases
The decision for an intervention with curative intent
is made by the members of the interdisciplinary
team at the participating institution.
￿ Course of tumour markers:
The course of the tumour markers carcinoembryonic
antigen (CEA) and carbohydrate antigen (CA) 19-9
will be monitored in both study arms during the
course of therapy. It is a secondary objective to
evaluate the influence of primary tumour resection
on the circulating levels of these tumour markers.
￿ Quality of Life:
Quality of life is measured using the EQ-5D™ ques-
tionnaire of the EuroQol Group. In addition, the
EORTC QLQ-C30 instrument and the specific color-
ectal module CR29 is used.
Trial implementation
There are 14 pre-specified study visits (V1 - V14) within
the SYNCHRONOUS trial. In V1 patients will be
screened according to the eligibility criteria and asked
for written informed consent. Within V1 participating
patients are also asked to complete the first quality-of-
life form.
After enrolment into the study patients will be allo-
cated randomly to either study arm (V2). The protocol
requires that the actual start of therapy (i.e. resection of
the primary tumour or first cycle of systemic therapy) is
carried out within 2 weeks after randomisation to
ensure comparable follow-up periods within and
between both study arms. An additional visit (Visit 2a)
will be performed in patients allocated to the experi-
mental arm to assess early postoperative outcomes until
post-operative day 30 (± 7 days). After randomisation
patients will be followed-up every 3 months (± 7 days)
in both study arms. The frequency and scope of study
visits are in line with routine clinical care of patients
with metastatic colon cancer. In these study visits (V3 -
V14) data on the primary endpoint and secondary end-
points are documented including data on safety, compli-
cations, administered therapies (chemotherapy
protocols, interventional therapies and surgical proce-
dures) and tumour markers. In addition, quality of life
will be assessed on V3 (3 months after V2), V4 (6
months after V2) and then every 6 months (i.e. on V6,
V8, V10, V12, V14). V14 is the end-of-study visit, which
will take place at a maximum of 36 months follow-up
after V2. Peri-operative laboratory tests and those dur-
ing chemotherapy cycles will be performed at discretion
of the executing investigator based on local standards.
Table 1 summarises the intended frequency and scope
of study visits.
Sample size
Based on the results obtained from a literature search, a
median overall survival time of 20 months is expected
for the control group (Fuchs et al. [12], Saltz et al. [13],
Van Cutsem et al. [23], Souglakos et al. [21], Seymour
et al. [11]). An improvement to 26 months by the surgi-
cal intervention is considered to be clinically relevant
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butt et al. [15]). For exponentially distributed survival
times, this treatment group difference corresponds to a
hazard ratio of 1.3. The accrual period amounts to 24
months and the follow-up period to 36 months. To
detect a hazard ratio of 1.3 with a two-sided test for
treatment effect at a significance level of 5% within a
Cox model without covariates with a power of 85%, 694
patients (347 per group) have to be included in the ana-
lysis, leading to a total number of events of 522. These
calculations are based on the formula for the log-rank
test [24] and were performed with ADDPLAN 5.0. Due
to the asymptotic equivalence of the test statistic of the
Cox model without covariates and the log-rank test sta-
tistics under the assumed model, the sample size calcu-
lation holds also true for the unadjusted Cox model. It
can be expected that inclusion of the covariates centre,
age, and administered systemic therapy in the analysis
will further increase the power as compared to the
above calculations that are based on the Cox model
without covariates.
Based on the current knowledge about the treatments
under investigation, it could not be ruled out that the
experimental intervention may show no effect or even a
negative effect in the early part of the follow-up as com-
pared to the control group, and that its advantage
becomes clear later on. To assess the robustness of the
study power, simulations were performed for various
parameter scenarios reflecting this situation. A linear
increase of the mortality in the control group and an
instantaneous increase in the experimental group by
rates between 5% and 10% during the first three months
of the follow-up were considered. Crossing of the
survival curves was assumed to occur after three months
and exponential survival thereafter leading overall to the
same median survival times as specified above. For the
sample size of 694 patients, the resulting power for the
two-sided test for treatment effect within the Cox model
without covariates varied between 84.5% and 90.3% thus
demonstrating robustness of the study power to the
assumptions made with respect to the course of the sur-
vival curves (simulations performed in SAS, version 9.1;
100,000 replications were performed for each parameter
scenario). We repeated these simulations, but now
applying the robust test proposed by Lin and Wei [25]
which will be applied in the analysis. For the robust test,
power values in the range from 84.6% to 90.5% were
obtained. Furthermore, considering the same scenarios
we performed simulations under the null hypothesis.
The estimated type I error rate for a nominal two-sided
significance level of 5% were between 4.95% and 5.08%
for the standard Cox model and between 4.78% and
4.98% for the robust approach. It can be concluded that
the robust test leads to virtually the same power in the
realistic scenarios we considered in our simulations
while at the same time assuring appropriate type I error
rate even if the proportional hazards assumption is
violated.
The loss-to-follow up rate can be assumed to be very
low (less than 1% in Van Cutsem et al. [23]). However,
it is expected that in the experimental group a number
of patients will not receive standard systemic treatment
after resection of the primary colon tumour (about 20%;
see Ruo et al. [14]). Furthermore, some patients will
stop standard systemic treatment early due to lack of
tolerability (about 20%; see Saltz et al. [13]). Although
Table 1 Investigation scheme in the SYNCHRONOUS trial
Documentation Visit 1 Visit 2 Visit 2a
1) Visit 3 - 13 Visit 14
Screening Maximum 2 weeks before start of
therapy
30 days after
surgery
q 3 months after
V2
36 months after
V2
Eligibility criteria X
Baseline data, demographics X
Laboratory analyses X
Tumor markers XX X
Randomization X
Administered therapies XX X
Chronic use of analgetic
medication
XX X
Assessment of com-plications &
safety
XX X
Primary endpoint XX X
Secondary endpoints X XX
Quality of life XX
2) X
1) Visit 2a will be performed in patients allocated to the experimental arm only.
2) Quality of life will be assessed on V3 (3 months after V2), V4, (6 months) and
then every 6 months
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analysis, there might be some dilution of the treatment
effect due to these protocol violations. This is accounted
for by randomising further 15% of the calculated num-
ber of patients, i.e., a total of 800 patients (400 per
group). It is assumed that further 100 patients will have
to be screened to achieve this number of randomised
patients.
Statistical analysis
Confirmatory analysis
The confirmatory analysis of the primary efficacy end-
point will be conducted according to the intention-to-
treat principle, i.e., all randomised patients will be
included and will be analysed in the treatment group
where they were allocated to by randomisation. The
test for treatment group difference will be performed
at the two-sided type I error rate 5% within a Cox pro-
portional hazards model that takes into account the
covariates centre, age, and administered systemic ther-
apy. The robust sandwich estimate of the covariance
matrix proposed by Lin and Wei [25] is used for the
test for treatment effect. As shown in [25], this test
allows valid statistical inference also in situations
where the proportional hazards assumption is violated,
which may be the case in the current trial. Drop-out
and lost-to-follow-up as well as non-occurrence of
death within the follow-up period are treated as cen-
soring events. Overall survival will be displayed for
each intervention group based on the Kaplan-Meier
estimates as well as on the estimates obtained from
the Cox regression model, and the corresponding two-
sided 95% confidence interval for the hazard ratio will
be calculated.
No interim analysis is planned for this trial. As the
follow-up for the primary endpoint is 36 months, and
the planned recruitment time 24 months, the results of
an interim analysis would arise after completion of the
recruitment and treatment period. Accordingly, an
interim analysis could not cause a reduction in sample
size and was therefore not implemented.
Further analyses
Descriptive methods will be used for the analysis of the
secondary outcomes. Time-to-event endpoints will be
analysed as described for the primary endpoint. Binary
secondary endpoints will be analysed using logistic
regression models. Appropriate summary measures of
the empirical distributions as well as descriptive p-values
will be calculated. Graphical methods will be applied to
visualise the findings of the study. Additionally, sensitiv-
ity analyses will be conducted for different populations
(per protocol population of those patients that show no
relevant protocol violations, appropriate subgroups).
The safety analysis will be based on all randomised
patients who were treated with any of the interventions
under investigation. The analysis will include calculation
and comparison of the rates of complications and ser-
ious adverse events as well as graphical display of the
time-course. All analyses will be done using SAS version
9.1 or higher.
Data management and quality assurance
The investigator or a designated representative must
enter all protocol-required information in the electronic
case report form (eCRF). Any entry and correction in
the Remote Data Entry System will be documented
automatically in an audit file. Once the documentation
of a patient is completed and checked for plausibility
the investigator is asked to date and sign it via electro-
nic identification. Documentation of quality of life ques-
tionnaires will be done on paper based questionnaires.
Control of data consistency
Automatic checks for data completeness, validity and
plausibility will be programmed by the data manage-
ment group of the Institute of Medical Biometry and
Informatics (IMBI), University of Heidelberg, and
queries will be generated. The investigator or the desig-
nated representatives are obliged to clarify or explain
the queries. If no further corrections are to be made in
the database, it will be closed and used for statistical
analysis. All data management procedures will be carried
out according to the current Standard Operating Proce-
dures (SOPs) of the IMBI.
Quality control and monitoring
Clinical monitoring will be performed by the Coordina-
tion Centre for Clinical Trials (KKS) Heidelberg, an
institution which is independent from other trial staff.
Monitoring procedures will be adapted to the study spe-
cific risk for the patients. Interpretation of standard
operating procedures (SOP) of the KKS to ensure
patients’ safety and integrity of the clinical data, e.g. pri-
mary endpoint in adherence to study protocol. Pre-
study visits will be performed in centres interested to
participate in the study, to ensure high compliance qual-
ity of the participating centres concerning e.g. patient
recruitment and documentation.
External monitoring of entries in the electronic CRF
will be done by independent monitors from KKS Heidel-
berg. Regular on-site monitoring visits are planned at all
sites depending on the recruitment rate and quality of
the data. Monitoring strategy and extent of source data
verification (SDV) are described in a trial specific moni-
toring manual.
Ethical and legal considerations
The SYNCHRONOUS trial is conducted in line with
either the Declaration of Helsinki (Tokyo, Venice, Hong
Kong, Somerset West and Edinburgh amendments) or
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Page 8 of 11the laws and regulations of the country, whichever pro-
vides the greatest protection of the patient.
The protocol has been written, and the study will be
conducted according to the ICH Harmonized Tripartite
Guideline for Good Clinical Practice http://www.ifpma.
org/pdfifpma/e6.pdf.
The trial protocol, patient information and informed
consent sheets have been approved by the independent
ethics committee of the University of Heidelberg, Medi-
cal School (S-073/2011) and by the competent ethics
committees of all participating trial centres. The SYN-
CHRONOUS trial has been registered at the ISRCTN
database (ISRCTN30964555; http://www.isrctn.org).
All patients will be informed of the aims of the study,
the possible adverse events, the procedures and possible
hazards to which he/she will be exposed, and the
mechanism of treatment allocation. Furthermore, it is
the responsibility of the investigator to explain patients
their duties within the trial. They will be informed as to
the strict confidentiality of their patient data, but that
their medical records may be reviewed for trial purposes
by authorised individuals other than their treating physi-
cian. An example of a patient informed consent state-
ment is given as an appendix to this protocol.
During the trial, patients will be identified solely by
means of their year of birth and individual identification
code (screening number, randomisation number). Trial
findings will be stored in accordance with local data
protection law/ICH GCP-Guidelines and will be handled
in strictest confidence. For protection of these data,
organisational procedures are implemented to prevent
distribution of data to unauthorised people.
Trial sponsorship and funding
The SYNCHRONOUS trial is sponsored by the Univer-
sitätsklinikum Heidelberg, represented by the Commer-
cial Director. The trial is funded exclusively by the
Deutsche Forschungsgemeinschaft (WE 3548/5-1).
Current status
The trial protocol has been approved by the indepen-
dent ethics committee of the University of Heidelberg,
Medical School. At the time of manuscript preparation
applications have been sent to the majority of the
affiliated local ethics committees of the participating
institutions.
Prior to the start of the study, all participating centres
were trained and introduced into all study specific pro-
cedures. For this purpose an investigator’sm e e t i n gw a s
held in Heidelberg in October 2011. During this two-
day workshop investigators and study nurses from the
participating institutions were instructed in the general
principles of clinical trials (day one) and the study speci-
fic implementation of the SYNCHRONOUS trial (day
two). The commitment of all participating institutions
to include patients in this important trial was strength-
ened and the participants used the opportunity to dis-
cuss protocol specific subjects and exchanged their
experience from previous randomized controlled trials.
As recruitment of patients was considered a critical
point of the study, the participants expressed their
strong will to ensure sufficient recruitment of patients
and discussed strategies to optimize patient recruitment.
Discussion
The SYNCHRONOUS trial is designed to evaluate effi-
cacy and safety of primary tumour resection prior to
systemic chemotherapy in patients with newly diagnosed
CRC and synchronous, unresectable metastases. Even
though enormous progress has been made in the treat-
ment of patients with CRC within the past three decades
[26], the optimal management of patients with meta-
static disease not amenable to curative therapy who pre-
sent without severe primary tumour related symptoms
has remained controversial. While randomised con-
trolled trials on patients with renal cell carcinoma
showed a survival benefit by removal of the primary
tumour [6,7], there has been a lack of well-designed and
controlled trials on the prognostic value of primary
tumour resection in CRC as indicated by two systematic
reviews [5,10].
In the SYNCHRONOUS trial the two strategies of pri-
mary tumour resection prior to chemotherapy and
immediate chemotherapy without previous resection of
the primary tumour are compared in a prospective, ran-
domised fashion. One should note that within this trial
two therapeutic strategies are compared rather than two
specific therapies with the aim to increase external
validity and ensure feasibility. For this reason there is no
pre-specified chemotherapy regimen to be applied
within the study arms of the trial and the choice for the
chemotherapy protocol is at discretion of the medical
oncologist in charge at each participating institution
considering current guidelines. However, the applied
chemotherapy in both study arms is documented accu-
rately and will be included as a covariate in the multi-
variate analysis. Similarly, the study protocol does not
call for specific surgical procedures for primary tumour
resection that should rather be performed in line with
the standards of the participating institution, the
patient’s condition, the location of the tumour and the
surgeon’s preference. Colonic resection may therefore be
performed laparoscopically or via laparotomy. Further-
more, the executing surgeon may decide whether or not
to create a primary anastomosis. As in selected patients
therapy with modern chemotherapy protocols may
cause marked tumour regression that may enable
further therapeutic action with curative intent, colonic
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mended, though this is not mandatory requirement and
the decision to perform lymphadenectomy remains at
the discretion of the executing surgeon. However,
patients who become candidates for curative resection
after responding to chemotherapy may receive further
treatment with curative intent. Additional treatments
will be documented and these patients will be analysed
within the intention-to-treat population.
Conclusion
The SYNCHRONOUS trial is a multicentre, randomised
controlled trial to evaluate efficacy and safety of primary
tumour resection in patients with metastatic colon can-
cer who do not suffer from local symptoms of the pri-
mary tumour. Its results may help to optimise the
management of colon cancer patients who are not
amenable to curative therapy.
Funding
This trial is funded by the Deutsche Forschungsge-
meinschaft (WE 3548/5-1)
Additional material
Additional file 1: Classification of perioperative complications.
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